Joshua F Baker1, Mikkel Ostergaard2, Michael George3, Justine Shults4, Paul Emery5, Daniel G Baker6, Philip G Conaghan5. 1. Division of Rheumatology, Philadelphia Veterans' Affairs Medical Center, Philadelphia, Pennsylvania, USA Division of Rheumatology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3. Division of Rheumatology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA. 4. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 5. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK. 6. Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Abstract
INTRODUCTION: Greater body mass index (BMI) has been associated with less radiographic progression in rheumatoid arthritis (RA). We evaluated the association between BMI and joint damage progression as measured by X-ray and MRI. METHODS: 1068 subjects with RA from two clinical trials of golimumab (GO-BEFORE and GO-FORWARD) had radiographs performed at weeks 0, 52 and 104 and evaluated using the van der Heijde-Sharp (vdHS) scoring system. Contrast-enhanced MRIs of the dominant wrist and hand were obtained at weeks 0, 12, 24, 52 and 104. Multivariable logistic regression evaluated the risk of radiographic progression for each BMI category (<25, 25-30, >30 kg/m(2)). Within GO-BEFORE, piecewise, robust generalised estimating equations marginal models assessed the probability of MRI erosion progression for each BMI category. Multivariable linear regression models assessed baseline associations between BMI and bone oedema (a precursor of bone erosion). RESULTS: Higher BMI category was associated with a lower probability of progression in vdHS score at weeks 52 and 104 independent of potential confounders. Higher BMI was also independently associated with a lower probability of progression in MRI erosion score over 2 years. Subjects with greater BMI demonstrated less bone oedema independent of differences in other disease severity measures, including MRI synovitis in the same joints. CONCLUSIONS: Greater BMI is associated with a lower risk of progression on X-ray and MRI over 2 years. Subjects with greater BMI also demonstrate less bone oedema at baseline. Greater BMI may indicate a less aggressive RA phenotype and aid in risk stratification. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
INTRODUCTION: Greater body mass index (BMI) has been associated with less radiographic progression in rheumatoid arthritis (RA). We evaluated the association between BMI and joint damage progression as measured by X-ray and MRI. METHODS: 1068 subjects with RA from two clinical trials of golimumab (GO-BEFORE and GO-FORWARD) had radiographs performed at weeks 0, 52 and 104 and evaluated using the van der Heijde-Sharp (vdHS) scoring system. Contrast-enhanced MRIs of the dominant wrist and hand were obtained at weeks 0, 12, 24, 52 and 104. Multivariable logistic regression evaluated the risk of radiographic progression for each BMI category (<25, 25-30, >30 kg/m(2)). Within GO-BEFORE, piecewise, robust generalised estimating equations marginal models assessed the probability of MRI erosion progression for each BMI category. Multivariable linear regression models assessed baseline associations between BMI and bone oedema (a precursor of bone erosion). RESULTS: Higher BMI category was associated with a lower probability of progression in vdHS score at weeks 52 and 104 independent of potential confounders. Higher BMI was also independently associated with a lower probability of progression in MRI erosion score over 2 years. Subjects with greater BMI demonstrated less bone oedema independent of differences in other disease severity measures, including MRI synovitis in the same joints. CONCLUSIONS: Greater BMI is associated with a lower risk of progression on X-ray and MRI over 2 years. Subjects with greater BMI also demonstrate less bone oedema at baseline. Greater BMI may indicate a less aggressive RA phenotype and aid in risk stratification. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Epidemiology; Magnetic Resonance Imaging; Rheumatoid Arthritis
Authors: Joshua F Baker; Philip G Conaghan; Josef S Smolen; Daniel Aletaha; Justine Shults; Paul Emery; Daniel G Baker; Mikkel Ostergaard Journal: Arthritis Rheumatol Date: 2014-04 Impact factor: 10.995
Authors: Edward Keystone; Mark C Genovese; Lars Klareskog; Elizabeth C Hsia; Stephen Hall; Pedro C Miranda; Jacek Pazdur; Sang-Cheol Bae; William Palmer; Stephen Xu; Mahboob U Rahman Journal: Ann Rheum Dis Date: 2010-05-05 Impact factor: 19.103
Authors: Joshua F Baker; Michael George; Daniel G Baker; Gary Toedter; Joan M Von Feldt; Mary B Leonard Journal: Rheumatology (Oxford) Date: 2011-09-02 Impact factor: 7.580
Authors: Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; Zhenhua Xu; John Han; Peter Taylor Journal: Arthritis Rheum Date: 2010-04
Authors: A H M van der Helm-van Mil; S M van der Kooij; C F Allaart; R E M Toes; T W J Huizinga Journal: Ann Rheum Dis Date: 2007-10-26 Impact factor: 19.103
Authors: Joshua F Baker; Mikkel Ostergaard; Paul Emery; Elizabeth C Hsia; Jiandong Lu; Daniel G Baker; Philip G Conaghan Journal: Ann Rheum Dis Date: 2013-07-31 Impact factor: 19.103
Authors: Joshua F Baker; Grant W Cannon; Said Ibrahim; Candace Haroldsen; Liron Caplan; Ted R Mikuls Journal: J Rheumatol Date: 2015-04-01 Impact factor: 4.666
Authors: Joshua F Baker; Bryant R England; Ted R Mikuls; Harlan Sayles; Grant W Cannon; Brian C Sauer; Michael D George; Liron Caplan; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2018-12 Impact factor: 4.794
Authors: Yongjia Li; Wei Zou; Jonathan R Brestoff; Nidhi Rohatgi; Xiaobo Wu; John P Atkinson; Charles A Harris; Steven L Teitelbaum Journal: Cell Rep Date: 2019-06-04 Impact factor: 9.423
Authors: Joshua F Baker; Philip G Conaghan; Paul Emery; Daniel G Baker; Mikkel Østergaard Journal: Ann Rheum Dis Date: 2015-06-19 Impact factor: 19.103
Authors: Florenzo Iannone; Delphine S Courvoisier; Jacques Eric Gottenberg; Maria Victoria Hernandez; Elisabeth Lie; Helena Canhão; Karel Pavelka; Merete Lund Hetland; Carl Turesson; Xavier Mariette; Denis Choquette; Axel Finckh Journal: Clin Rheumatol Date: 2016-12-14 Impact factor: 2.980